AU726634B2 - Salt of naphthyridine carboxylic acid derivative - Google Patents
Salt of naphthyridine carboxylic acid derivative Download PDFInfo
- Publication number
- AU726634B2 AU726634B2 AU66366/98A AU6636698A AU726634B2 AU 726634 B2 AU726634 B2 AU 726634B2 AU 66366/98 A AU66366/98 A AU 66366/98A AU 6636698 A AU6636698 A AU 6636698A AU 726634 B2 AU726634 B2 AU 726634B2
- Authority
- AU
- Australia
- Prior art keywords
- compound according
- methanesulfonate
- carboxylic acid
- naphthyridine
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003839 salts Chemical class 0.000 title description 6
- SNLMOXFUCILIPL-UHFFFAOYSA-N 1,8-naphthyridine-2-carboxylic acid Chemical class C1=CC=NC2=NC(C(=O)O)=CC=C21 SNLMOXFUCILIPL-UHFFFAOYSA-N 0.000 title 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 87
- 239000012453 solvate Substances 0.000 claims description 45
- 238000002441 X-ray diffraction Methods 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 11
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 9
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 230000036571 hydration Effects 0.000 claims description 8
- 238000006703 hydration reaction Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- JIYMVSQRGZEYAX-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1C(CN)C(=NOC)CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 JIYMVSQRGZEYAX-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 59
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 150000004677 hydrates Chemical class 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 22
- 229910001873 dinitrogen Inorganic materials 0.000 description 16
- 239000012458 free base Substances 0.000 description 13
- 238000001179 sorption measurement Methods 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OIXMUQLVDNPHNS-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical class O.CS(O)(=O)=O OIXMUQLVDNPHNS-UHFFFAOYSA-N 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- -1 3 -aminomethyl-4-methoxyiminopyrrolidin-1-yl Chemical group 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000005979 thermal decomposition reaction Methods 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- CIMIGBCQBKCGOR-UHFFFAOYSA-N 1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)=CNC2=N1 CIMIGBCQBKCGOR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000588697 Enterobacter cloacae Species 0.000 description 2
- 101000740462 Escherichia coli Beta-lactamase TEM Proteins 0.000 description 2
- 238000001159 Fisher's combined probability test Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000002076 thermal analysis method Methods 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- SOUXXQBODCTMBK-UHFFFAOYSA-N CS(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.S(O)(O)(=O)=O.C(=O)(O)C(O)C(O)C(=O)O Chemical compound CS(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.S(O)(O)(=O)=O.C(=O)(O)C(O)C(O)C(=O)O SOUXXQBODCTMBK-UHFFFAOYSA-N 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000002221 gravimetric sorption analysis Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR19970009840 | 1997-03-21 | ||
| KR1997/9840 | 1997-03-21 | ||
| PCT/KR1998/000051 WO1998042705A1 (en) | 1997-03-21 | 1998-03-20 | Salt of naphthyridine carboxylic acid derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6636698A AU6636698A (en) | 1998-10-20 |
| AU726634B2 true AU726634B2 (en) | 2000-11-16 |
Family
ID=19500439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU66366/98A Expired AU726634B2 (en) | 1997-03-21 | 1998-03-20 | Salt of naphthyridine carboxylic acid derivative |
Country Status (38)
| Country | Link |
|---|---|
| US (9) | US7700617B2 (OSRAM) |
| EP (2) | EP1179533B1 (OSRAM) |
| JP (3) | JP3759962B2 (OSRAM) |
| KR (1) | KR100266499B1 (OSRAM) |
| CN (1) | CN1131229C (OSRAM) |
| AP (1) | AP1331A (OSRAM) |
| AR (1) | AR012125A1 (OSRAM) |
| AT (2) | ATE257836T1 (OSRAM) |
| AU (1) | AU726634B2 (OSRAM) |
| BG (1) | BG63972B1 (OSRAM) |
| BR (1) | BR9808290A (OSRAM) |
| CA (1) | CA2283671C (OSRAM) |
| CZ (2) | CZ288673B6 (OSRAM) |
| DE (2) | DE69814378T2 (OSRAM) |
| DK (2) | DK0981527T3 (OSRAM) |
| DZ (1) | DZ2448A1 (OSRAM) |
| EA (1) | EA001674B1 (OSRAM) |
| ES (2) | ES2198697T3 (OSRAM) |
| HU (2) | HU225412B1 (OSRAM) |
| ID (1) | ID22681A (OSRAM) |
| IL (2) | IL131812A (OSRAM) |
| IN (1) | IN188178B (OSRAM) |
| IS (2) | IS2093B (OSRAM) |
| MA (1) | MA24500A1 (OSRAM) |
| MY (1) | MY137653A (OSRAM) |
| NO (1) | NO312515B1 (OSRAM) |
| NZ (1) | NZ337748A (OSRAM) |
| OA (1) | OA11161A (OSRAM) |
| PE (1) | PE67999A1 (OSRAM) |
| PL (1) | PL191815B1 (OSRAM) |
| PT (2) | PT981527E (OSRAM) |
| SA (1) | SA98181055B1 (OSRAM) |
| SI (2) | SI1179533T1 (OSRAM) |
| SK (1) | SK284107B6 (OSRAM) |
| TR (1) | TR199902313T2 (OSRAM) |
| UA (1) | UA56218C2 (OSRAM) |
| WO (1) | WO1998042705A1 (OSRAM) |
| ZA (1) | ZA982335B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9820405D0 (en) | 1998-09-18 | 1998-11-11 | Smithkline Beecham Plc | Process |
| CA2366660A1 (en) * | 1999-03-19 | 2000-09-28 | Carl M. Mendel | Treatment of osteoarthritis |
| US6331550B1 (en) | 1999-06-29 | 2001-12-18 | Smithkline Beecham Corporation | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
| US6262071B1 (en) | 1999-06-29 | 2001-07-17 | Smithkline Beecham Corporation | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
| US6803376B1 (en) | 1999-06-29 | 2004-10-12 | Smithkline Beecham Corporation | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
| CA2282066C (en) | 1999-06-29 | 2010-09-07 | Smithkline Beecham Corporation | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
| GB9920919D0 (en) * | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel compound |
| GB9920917D0 (en) * | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel process |
| JP2001097891A (ja) * | 1999-09-24 | 2001-04-10 | Smithkline Beecham Corp | 呼吸器系病原菌に対するフルオロキノロン化合物の使用法 |
| JP2001097863A (ja) * | 1999-09-24 | 2001-04-10 | Smithkline Beecham Corp | 嫌気性病原菌に対するフルオロキノロン化合物の使用法 |
| AU7709400A (en) * | 1999-09-22 | 2001-04-24 | Smithkline Beecham Corporation | Methods of use of fluoroquinolone compounds against bacteria |
| JP2001097864A (ja) * | 1999-09-24 | 2001-04-10 | Smithkline Beecham Corp | 呼吸管および尿路病原性細菌に対するフルオロキノリン化合物の使用方法 |
| GR1003520B (el) * | 1999-09-22 | 2001-01-22 | Smithkline Beecham Plc | Μεθοδος χρησης ενωσεων φλουοροκινολονης εναντια σε νοσοκομειακα αρνητικα κατα gramμ παθογενων βακτηριδιων |
| GR1003521B (el) * | 1999-09-23 | 2001-01-22 | Smithkline Beecham Plc | Μεθοδοι χρησεως ενωσεων φλουοροκινολονης εναντια κατα gram θετικων παθογονων βακτηριδιων |
| KR20010091379A (ko) * | 2000-03-15 | 2001-10-23 | 성재갑 | 7-(4-아미노메틸-3-옥심)피롤리딘 치환체를 갖는 퀴놀린카르복실산 유도체의 신규 제조방법 |
| SI1412078T1 (sl) | 2001-08-02 | 2009-04-30 | Lg Life Sciences Ltd Lg Twin T | Postopki za pripravo amino-zaščitenih derivatov 4-aminometilen-pirolidin-3-ona, gemifloksacina ali njegove soli |
| ATE372119T1 (de) * | 2001-11-30 | 2007-09-15 | Lg Life Sciences Ltd | Verfahren zur behandlung von bakteriellen infektionen mit gemifloxacin oder einem seiner salze und einem beta-lactam-antibiotikum |
| KR100517638B1 (ko) | 2002-04-08 | 2005-09-28 | 주식회사 엘지생명과학 | 게미플록사신 산염의 새로운 제조방법 |
| AR043880A1 (es) * | 2003-04-22 | 2005-08-17 | Solvay Pharm Gmbh | Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas |
| EP1891037A1 (en) * | 2005-06-15 | 2008-02-27 | Hetero Drugs Limited | Gemifloxacin process and polymorphs |
| CN101500564B (zh) * | 2006-03-07 | 2012-07-25 | 沃克哈特有限公司 | 苯并喹嗪-2-羧酸的前药 |
| WO2010001408A2 (en) * | 2008-06-06 | 2010-01-07 | Matrix Laboratories Ltd. | Novel polymorphic forms of gemifloxacin mesylate |
| WO2010146594A1 (en) * | 2009-06-16 | 2010-12-23 | Hetero Research Foundation | Novel polymorphs of gemifloxacin mesylate |
| EP2491921A1 (en) | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Conservation of anhydrous form of gemifloxacin |
| SG11201404834XA (en) * | 2012-02-27 | 2014-09-26 | Bristol Myers Squibb Co | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
| CZ2016104A3 (cs) * | 2016-02-24 | 2017-09-06 | Zentiva, K.S. | Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR223983A1 (es) | 1978-08-25 | 1981-10-15 | Dainippon Pharmaceutical Co | Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico |
| ES8304117A1 (es) | 1981-06-11 | 1983-02-16 | Warner Lambert Co | "un procedimiento para preparar sales de compuestos de naftiridina y quinoleina". |
| IN162769B (OSRAM) | 1984-11-13 | 1988-07-09 | Kyorin Seiyaku Kk | |
| NZ222047A (en) | 1986-10-08 | 1991-01-29 | Bristol Myers Co | Quinoline - or naphthyridine - carboxylic acid anti-bacterial agents |
| JPH01100165A (ja) | 1987-10-13 | 1989-04-18 | Shionogi & Co Ltd | オキシムまたはヒドロキシアミン誘導体系抗菌剤 |
| US4920120A (en) | 1988-01-25 | 1990-04-24 | Warner-Lambert Company | Antibacterial agents |
| US4931446A (en) * | 1988-03-23 | 1990-06-05 | Abbott Laboratories | Antimicrobial for in-vitro diagnostic kits |
| US5286723A (en) * | 1988-08-31 | 1994-02-15 | Daiichi Seiyaku Co., Ltd. | Spiro compound |
| CA1336090C (en) * | 1988-08-31 | 1995-06-27 | Isao Hayakawa | Spiro-substituted cyclic amines of quinolone derivatives |
| PL166381B1 (pl) | 1989-08-16 | 1995-05-31 | Pfizer | Sposób wytwarzania nowych podstawionych kwasów 7-azabicyklochinolonokarboksylowych PL PL PL PL |
| EP0541086A1 (en) | 1991-11-08 | 1993-05-12 | Kaken Pharmaceutical Co., Ltd. | Antibacterial 6-fluoro-quinolones having an oxime group on the substituent in position 7 |
| WO1993025545A1 (en) | 1992-06-09 | 1993-12-23 | Korea Research Institute Of Chemical Technology | Novel quinoline derivatives and processes for preparing the same |
| US5776944A (en) * | 1994-06-16 | 1998-07-07 | Lg Chemical Ltd. | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
| EP0688772B1 (en) * | 1994-06-16 | 1999-05-06 | LG Chemical Limited | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation |
| DE69531305T2 (de) | 1994-10-20 | 2004-05-13 | Wakunaga Seiyaku K.K. | Pyridoncarboxylat- derivate oder salze davon und antibakterielle zusammensetzungen die diese als aktiven bestandteil enthalten |
| CA2211681C (en) | 1995-01-30 | 2003-05-13 | Wakunaga Seiyaku Kabushiki Kaisha | Novel pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents comprising the same as active ingredient |
| JP3145715B2 (ja) | 1995-06-06 | 2001-03-12 | ファイザー・インコーポレーテッド | 無水７−（［１α，５α，６α］−６−アミノ−３−アザビシクロ［３．１．０］ヘキサ−３−イル）−６−フルオロ−１−（２，４−ジフルオロフェニル）−１，４−ジヒドロ−４−オキソ−１，８−ナフチリディン−３−カルボン酸メタンスルホン酸塩の新規な結晶形態 |
| US20020032216A1 (en) * | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
| KR100286874B1 (ko) * | 1998-03-04 | 2001-04-16 | 성재갑 | 보호된 4-아미노메틸-피롤리딘-3-온의 제조방법 |
| GB9820405D0 (en) | 1998-09-18 | 1998-11-11 | Smithkline Beecham Plc | Process |
-
1998
- 1998-03-17 MA MA25001A patent/MA24500A1/fr unknown
- 1998-03-18 DZ DZ980058A patent/DZ2448A1/xx active
- 1998-03-19 ZA ZA9802335A patent/ZA982335B/xx unknown
- 1998-03-20 AR ARP980101268A patent/AR012125A1/es active IP Right Grant
- 1998-03-20 CN CN98803576A patent/CN1131229C/zh not_active Expired - Lifetime
- 1998-03-20 AP APAP/P/1999/001649A patent/AP1331A/en active
- 1998-03-20 CA CA002283671A patent/CA2283671C/en not_active Expired - Lifetime
- 1998-03-20 NZ NZ337748A patent/NZ337748A/xx not_active IP Right Cessation
- 1998-03-20 PT PT98908300T patent/PT981527E/pt unknown
- 1998-03-20 WO PCT/KR1998/000051 patent/WO1998042705A1/en active IP Right Grant
- 1998-03-20 SI SI9830595T patent/SI1179533T1/ unknown
- 1998-03-20 BR BR9808290-6A patent/BR9808290A/pt not_active Application Discontinuation
- 1998-03-20 AT AT01203507T patent/ATE257836T1/de active
- 1998-03-20 UA UA99095186A patent/UA56218C2/uk unknown
- 1998-03-20 PE PE1998000202A patent/PE67999A1/es not_active Application Discontinuation
- 1998-03-20 AT AT98908300T patent/ATE239724T1/de active
- 1998-03-20 JP JP54550098A patent/JP3759962B2/ja not_active Expired - Lifetime
- 1998-03-20 PT PT01203507T patent/PT1179533E/pt unknown
- 1998-03-20 HU HU0000728A patent/HU225412B1/hu unknown
- 1998-03-20 DE DE69814378T patent/DE69814378T2/de not_active Expired - Lifetime
- 1998-03-20 TR TR1999/02313T patent/TR199902313T2/xx unknown
- 1998-03-20 DK DK98908300T patent/DK0981527T3/da active
- 1998-03-20 AU AU66366/98A patent/AU726634B2/en not_active Expired
- 1998-03-20 DE DE69821147T patent/DE69821147T2/de not_active Expired - Lifetime
- 1998-03-20 ID IDW991044A patent/ID22681A/id unknown
- 1998-03-20 IL IL131812A patent/IL131812A/en not_active IP Right Cessation
- 1998-03-20 EP EP01203507A patent/EP1179533B1/en not_active Expired - Lifetime
- 1998-03-20 SK SK1236-99A patent/SK284107B6/sk not_active IP Right Cessation
- 1998-03-20 SI SI9830418T patent/SI0981527T1/xx unknown
- 1998-03-20 ES ES98908300T patent/ES2198697T3/es not_active Expired - Lifetime
- 1998-03-20 KR KR1019980009717A patent/KR100266499B1/ko not_active Expired - Lifetime
- 1998-03-20 IL IL13181298A patent/IL131812A0/xx active IP Right Grant
- 1998-03-20 HU HU0600401A patent/HU227536B1/hu unknown
- 1998-03-20 EA EA199900855A patent/EA001674B1/ru not_active IP Right Cessation
- 1998-03-20 DK DK01203507T patent/DK1179533T3/da active
- 1998-03-20 CZ CZ19993282A patent/CZ288673B6/cs not_active IP Right Cessation
- 1998-03-20 PL PL335812A patent/PL191815B1/pl unknown
- 1998-03-20 ES ES01203507T patent/ES2213669T3/es not_active Expired - Lifetime
- 1998-03-20 EP EP98908300A patent/EP0981527B1/en not_active Expired - Lifetime
- 1998-03-21 MY MYPI98001236A patent/MY137653A/en unknown
- 1998-03-23 IN IN727DE1998 patent/IN188178B/en unknown
- 1998-03-25 SA SA98181055A patent/SA98181055B1/ar unknown
-
1999
- 1999-09-14 IS IS5181A patent/IS2093B/is unknown
- 1999-09-20 OA OA9900213A patent/OA11161A/fr unknown
- 1999-09-21 BG BG103750A patent/BG63972B1/bg unknown
- 1999-09-21 NO NO19994595A patent/NO312515B1/no not_active IP Right Cessation
-
2000
- 2000-10-03 CZ CZ20003641A patent/CZ288715B6/cs not_active IP Right Cessation
-
2003
- 2003-05-07 JP JP2003128650A patent/JP4781614B2/ja not_active Expired - Lifetime
-
2005
- 2005-07-21 IS IS7952A patent/IS2095B/is unknown
-
2006
- 2006-12-07 US US11/635,069 patent/US7700617B2/en not_active Expired - Fee Related
-
2008
- 2008-10-14 JP JP2008265345A patent/JP2009051851A/ja not_active Withdrawn
-
2009
- 2009-01-09 US US12/318,845 patent/US20090182006A1/en not_active Abandoned
-
2010
- 2010-06-02 US US12/791,957 patent/US20100240694A1/en not_active Abandoned
-
2011
- 2011-04-11 US US13/083,685 patent/US20110312987A1/en not_active Abandoned
-
2012
- 2012-06-26 US US13/533,383 patent/US20130065917A1/en not_active Abandoned
-
2013
- 2013-10-25 US US14/063,117 patent/US20140187576A1/en not_active Abandoned
-
2015
- 2015-02-13 US US14/621,689 patent/US20150291585A1/en not_active Abandoned
-
2016
- 2016-01-15 US US14/996,765 patent/US20160264569A1/en not_active Abandoned
-
2017
- 2017-01-20 US US15/411,030 patent/US20170253588A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU726634B2 (en) | Salt of naphthyridine carboxylic acid derivative | |
| US6723734B2 (en) | Salt of naphthyridine carboxylic acid derivative | |
| HK1045838B (en) | Salt of naphthyridine carboxylic acid derivative | |
| HK1045838A (en) | Salt of naphthyridine carboxylic acid derivative | |
| HK1026698B (en) | Salt of naphthyridine carboxylic acid derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: LG LIFE SCIENCES LTD. Free format text: FORMER OWNER WAS: LG CHEMICAL LTD. |